Corcept Therapeutics (NASDAQ:CORT) Given Overweight Rating at Piper Sandler

Corcept Therapeutics (NASDAQ:CORT)‘s stock had its “overweight” rating restated by investment analysts at Piper Sandler in a report released on Thursday,Benzinga reports. They currently have a $165.00 price objective on the biotechnology company’s stock, up from their prior price objective of $88.00. Piper Sandler’s price objective would suggest a potential upside of 39.84% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price on the stock. in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Corcept Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $119.17.

Corcept Therapeutics Price Performance

CORT traded up $25.05 on Thursday, hitting $118.00. 3,034,675 shares of the stock were exchanged, compared to its average volume of 1,592,158. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $122.21. The firm has a market capitalization of $12.67 billion, a price-to-earnings ratio of 337.52 and a beta of 0.47. The business has a 50-day moving average of $82.51 and a two-hundred day moving average of $55.80.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The company had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter in the previous year, the firm posted $0.29 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 31.7% on a year-over-year basis. Equities research analysts expect that Corcept Therapeutics will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director David L. Mahoney sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total value of $1,690,600.00. Following the transaction, the director owned 26,147 shares in the company, valued at $2,210,205.91. The trade was a 43.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Atabak Mokari sold 40,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $81.15, for a total transaction of $3,246,000.00. Following the completion of the transaction, the chief financial officer directly owned 16,130 shares of the company’s stock, valued at approximately $1,308,949.50. This represents a 71.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 300,000 shares of company stock worth $22,088,050. Insiders own 20.70% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CORT. Pathstone Holdings LLC increased its position in shares of Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares during the period. State of Wyoming grew its stake in Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after buying an additional 186 shares during the last quarter. Gould Capital LLC raised its position in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Corcept Therapeutics by 3.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 6,904 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 247 shares during the last quarter. Finally, Evergreen Capital Management LLC increased its holdings in shares of Corcept Therapeutics by 3.0% in the fourth quarter. Evergreen Capital Management LLC now owns 8,609 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 248 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings and revenue beat: Corcept reported adjusted earnings of $0.36 per share, versus the consensus estimate of $0.02, while revenue reached $256.15 million, ahead of the $221.15 million estimate. Revenue increased 31.7% year over year, with operating profit rising 54.8% to $41.3 million. Corcept Therapeutics Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: 2026 revenue outlook raised: Management now expects full-year revenue of approximately $1.1 billion to $1.2 billion, above the roughly $1.0 billion analyst consensus. The higher forecast signals continued confidence in commercial momentum. CORT Q2 Earnings and Revenues Beat Estimates, 2026 Outlook Raised
• Positive Sentiment: Product growth is supporting the business: Corcept cited continued Korlym growth and a strong Lifyorli launch, while net income increased to $42.1 million. The company ended the quarter with $111 million in cash and generated $33.5 million in operating cash flow. Corcept Therapeutics Announces Second Quarter Financial Results
• Neutral Sentiment: Valuation and trading risks remain: Following the rally, CORT trades at a very elevated earnings multiple, increasing sensitivity to future execution and guidance. Recent institutional activity was mixed, with some funds adding shares and others reducing positions.
• Negative Sentiment: Analyst downgrade and insider selling are cautionary signals: Wolfe Research downgraded the stock to Underperform, while reported insider activity over the past six months was dominated by sales rather than purchases. These factors could limit further gains despite the strong quarter. Wolfe Research Downgrades Corcept Therapeutics

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.